AI Article Synopsis

  • - Certain cancer treatments increase the risk of heart problems, highlighting the need for effective cardiovascular protection strategies, with statins showing promise due to their various beneficial properties.
  • - Statins have demonstrated protective effects against chemotherapy-induced heart damage and show potential in preclinical studies for mitigating effects of radiotherapy and certain immunotherapies, though human data is limited.
  • - The review discusses the underlying mechanisms of heart toxicity from anticancer therapies and the potential role of statins, while also calling for more extensive research into their protective effects in cancer patients undergoing treatment.

Article Abstract

Certain anticancer therapies inevitably increase the risk of cardiovascular events, now the second leading cause of death among cancer patients. This underscores the critical need for developing effective drugs or regimens for cardiovascular protection. Statins possess properties such as antioxidative stress, anti-inflammatory effects, antifibrotic activity, endothelial protection, and immune modulation. These pathological processes are central to the cardiotoxicity associated with anticancer treatment. There is prospective clinical evidence confirming the protective role of statins in chemotherapy-induced cardiotoxicity. Numerous preclinical studies have demonstrated that statins can ameliorate heart and endothelial damage caused by radiotherapy, although clinical studies are scarce. In the animal models of trastuzumab-induced cardiomyopathy, statins provide protection through anti-inflammatory, antioxidant, and antifibrotic mechanisms. In animal and cell models, statins can mitigate inflammation, endothelial damage, and cardiac injury induced by immune checkpoint inhibitors. Chimeric antigen receptor (CAR)-T cell therapy-induced cardiotoxicity and immune effector cell-associated neurotoxicity syndrome are associated with uncontrolled inflammation and immune activation. Due to their anti-inflammatory and immunomodulatory effects, statins have been used to manage CAR-T cell therapy-induced immune effector cell-associated neurotoxicity syndrome in a clinical trial. However, direct evidence proving that statins can mitigate CAR-T cell therapy-induced cardiotoxicity is still lacking. This review summarizes the possible mechanisms of anticancer therapy-induced cardiotoxicity and the potential mechanisms by which statins may reduce related cardiac damage. We also discuss the current status of research on the protective effect of statins in anticancer treatment-related cardiovascular disease and provide directions for future research. Additionally, we propose further studies on using statins for the prevention of cardiovascular disease in anticancer treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11432657PMC
http://dx.doi.org/10.3390/ijms251810177DOI Listing

Publication Analysis

Top Keywords

cardiovascular disease
12
car-t cell
12
cell therapy-induced
12
therapy-induced cardiotoxicity
12
statins
11
anticancer treatment-related
8
treatment-related cardiovascular
8
disease anticancer
8
anticancer treatment
8
endothelial damage
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!